debt_leverage_profile
0.82x Total Debt / Equity (Moderate leverage)
High
SEC-XBRL
interest_rate_sensitivity
Moderate-high; ~$200M+ in debt/convertible notes means 200bps rate rise adds ~$4M annual interest expense, pressuring cash burn
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Semiconductor components (Taiwan/Asia concentration) and specialized dialysis membrane materials (limited global suppliers)
Inferred
Agent_Inference
international_expansion_readiness
Minimal exposure; Outset is predominantly US-revenue (~95%+), with negligible international market penetration to date
Inferred
Agent_Inference
geographic_footprint
Effectively USD-denominated business; near-zero sovereign currency devaluation risk given ~95% US domestic revenue concentration
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Yes; proprietary cartridge consumables rely on sole-source or limited-source suppliers for key filtration and fluid-path components
Inferred
Agent_Inference
business_model_type_primary
Moderate disruption; cloud hosts software/analytics for Tablo console, but core device functionality is embedded—workaround feasible within 60-90 days
Inferred
Agent_Inference
business_model_type_secondary
Medical device hardware plus recurring consumable/service revenue; cloud dependency is secondary to physical product delivery
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; Outset's Tablo integrates with hospital EMR systems (Epic, Cerner) but is not deeply API-dependent for core revenue
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; revenue from medical device sales and consumables clearly constitutes product/service commerce, not an investment contract
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low-moderate; patient dialysis data triggers HIPAA primarily; GDPR exposure minimal given limited EU operations; CCPA applicable but manageable
Inferred
Agent_Inference
antitrust_exposure_flag
Low; Outset holds small share in a market dominated by Fresenius and Baxter; no credible monopolization or price-fixing exposure
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~40-50% recurring (consumables, service contracts, SaaS); ~50-60% transactional (capital equipment/Tablo console placements)
Inferred
Agent_Inference
monetization_vector
Razor-and-blade model: low-margin hardware placements drive high-margin recurring consumable and software revenue per machine
Inferred
Agent_Inference
pricing_architecture
Vulnerable to hospital GPO pressure and competitive bidding; consumable pricing relatively sticky once installed but capital price is negotiable
Inferred
Agent_Inference
pricing_power_rating
Moderate (6/10); clinical differentiation supports premium but hospital procurement committees and GPOs cap upside pricing leverage
Inferred
Agent_Inference
target_gross_margin_bracket
39.1% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
churn_vulnerability_index
Low free-rider risk; proprietary Tablo cartridges create captive consumable demand—no viable workaround for installed base
Inferred
Agent_Inference
headcount_cost_structure
Sublinear at scale; field clinical and sales headcount must grow with installations, but manufacturing and R&D costs plateau—semi-linear overall
Inferred
Agent_Inference
marginal_cost_of_growth
Moderate; doubling revenue requires ~60-70% headcount increase near-term given field support intensity, improving as installed base matures
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Outset operates a direct sales and service model with no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC should decline as brand recognition grows, but hospital sales cycles remain long (6-18 months), limiting CAC compression
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; data aggregation across Tablo fleet could create clinical insights moat, but network effect is not yet durable
Inferred
Agent_Inference
asset_efficiency_ratio
-30.6% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 2 (moderately resilient); dialysis is non-discretionary medical need, but hospital capital budget freezes in recessions delay Tablo purchases
Inferred
Agent_Inference
customer_segment_primary
Hospital acute care and in-center dialysis units; top 10 health systems likely represent 30-40% of installed base revenue
Inferred
Agent_Inference
customer_segment_secondary
Home dialysis patients and chronic kidney disease programs; growing segment but currently smaller revenue contribution than acute care
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.7% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001484612
High
SEC-EDGAR